FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2325367091> ?p ?o ?g. }

• W2325367091 endingPage "e2560" @default.
• W2325367091 startingPage "e2560" @default.
• W2325367091 abstract "Invasive fungal infection (IFI) remains as a significant cause of morbidity and mortality in patients with acute myelogenous leukemia (AML). Here, we report the subgroup analysis of China Assessment of Antifungal Therapy in Haematological Disease (CAESAR) study to evaluate the risk of IFI in patients with AML in 1st remission receiving high-dose cytarabine (HiDAC) as consolidation. A total of 638 patients with AML in 1st complete remission were selected from the database. Among them, 130 patients received HiDAC alone with total dose of 2–3 g/m2 × 6 while 508 patients received multiple-agent combination chemotherapy (multiagent chemo group). The patients’ characteristics were generally not different but more patients in HiDAC group had peripherally inserted central catheter (61.5% vs 44.5%, P = 0.002). The median duration of neutropenia was 8.0 days in both HiDAC (2–20) and multiagent chemo group (2–28). Number of patients with prolonged neutropenia (>14 days) tended to be more in multiagent chemo group but not significant different (16.3% vs 8.8%, respectively). There was no significant difference between 2 groups in persistent neutropenic fever (40.8% vs 33.1%), antifungal treatment (11.5% vs 11.4%), and incidence of proven/probable IFI (4 probable in HiDAC vs 1 proven/4 probable in multiagent chemo, P = 0.35) or possible IFI. As to the clinical outcome in terms of duration of hospitalization and death in remission, there was a trend of shorter duration of hospitalization in HiDAC (19 days, 3–70) compare to multiagent chemo group (21 days, 1–367, P = 0.057) while no death documented in HiDAC group and only 2 patients died in the multiagent chemo group (0.4%). As to risk factors associated with IFI in all 638 patients, there was a trend of more IFI in patients with severe neutropenia (3.0%, P = 0.089) and previous history of IFI (3.85%, P = 0.086) while the antifungal prophylaxis was not associated significantly reduced IFI. Overall, our data support the perception that HiDAC alone as consolidation in first remission AML patients was well tolerated and not associated with increased hematological toxicity and IFI than conventional combination chemotherapy. Antifungal prophylaxis may not necessary except for patients with previous history of IFI." @default.
• W2325367091 created "2016-06-24" @default.
• W2325367091 creator A5012541451 @default.
• W2325367091 creator A5013946920 @default.
• W2325367091 creator A5022597400 @default.
• W2325367091 creator A5028634125 @default.
• W2325367091 creator A5030968272 @default.
• W2325367091 creator A5034579434 @default.
• W2325367091 creator A5037029781 @default.
• W2325367091 creator A5038805449 @default.
• W2325367091 creator A5040795581 @default.
• W2325367091 creator A5043553316 @default.
• W2325367091 creator A5046615669 @default.
• W2325367091 creator A5057401157 @default.
• W2325367091 creator A5077384746 @default.
• W2325367091 creator A5079166921 @default.
• W2325367091 creator A5079218922 @default.
• W2325367091 creator A5082005832 @default.
• W2325367091 creator A5085612104 @default.
• W2325367091 creator A5087171601 @default.
• W2325367091 date "2016-01-01" @default.
• W2325367091 modified "2023-10-16" @default.
• W2325367091 title "Does High-Dose Cytarabine Cause More Fungal Infection in Patients With Acute Myeloid Leukemia Undergoing Consolidation Therapy" @default.
• W2325367091 cites W1492445977 @default.
• W2325367091 cites W1519562949 @default.
• W2325367091 cites W1556454749 @default.
• W2325367091 cites W1819112229 @default.
• W2325367091 cites W1963901245 @default.
• W2325367091 cites W1968735244 @default.
• W2325367091 cites W1969545468 @default.
• W2325367091 cites W2013522462 @default.
• W2325367091 cites W2022686977 @default.
• W2325367091 cites W2056158943 @default.
• W2325367091 cites W2059323804 @default.
• W2325367091 cites W2066420284 @default.
• W2325367091 cites W2072837701 @default.
• W2325367091 cites W2072940754 @default.
• W2325367091 cites W2093654759 @default.
• W2325367091 cites W2094493226 @default.
• W2325367091 cites W2105573850 @default.
• W2325367091 cites W2109088397 @default.
• W2325367091 cites W2123134253 @default.
• W2325367091 cites W2124680384 @default.
• W2325367091 cites W2134958070 @default.
• W2325367091 cites W2135672254 @default.
• W2325367091 cites W2148258556 @default.
• W2325367091 cites W2148883973 @default.
• W2325367091 cites W2166514247 @default.
• W2325367091 cites W2166734004 @default.
• W2325367091 cites W2167638087 @default.
• W2325367091 cites W2341266869 @default.
• W2325367091 doi "https://doi.org/10.1097/md.0000000000002560" @default.
• W2325367091 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5291567" @default.
• W2325367091 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26825897" @default.
• W2325367091 hasPublicationYear "2016" @default.
• W2325367091 type Work @default.
• W2325367091 sameAs 2325367091 @default.
• W2325367091 citedByCount "10" @default.
• W2325367091 countsByYear W23253670912016 @default.
• W2325367091 countsByYear W23253670912018 @default.
• W2325367091 countsByYear W23253670912019 @default.
• W2325367091 countsByYear W23253670912020 @default.
• W2325367091 countsByYear W23253670912023 @default.
• W2325367091 crossrefType "journal-article" @default.
• W2325367091 hasAuthorship W2325367091A5012541451 @default.
• W2325367091 hasAuthorship W2325367091A5013946920 @default.
• W2325367091 hasAuthorship W2325367091A5022597400 @default.
• W2325367091 hasAuthorship W2325367091A5028634125 @default.
• W2325367091 hasAuthorship W2325367091A5030968272 @default.
• W2325367091 hasAuthorship W2325367091A5034579434 @default.
• W2325367091 hasAuthorship W2325367091A5037029781 @default.
• W2325367091 hasAuthorship W2325367091A5038805449 @default.
• W2325367091 hasAuthorship W2325367091A5040795581 @default.
• W2325367091 hasAuthorship W2325367091A5043553316 @default.
• W2325367091 hasAuthorship W2325367091A5046615669 @default.
• W2325367091 hasAuthorship W2325367091A5057401157 @default.
• W2325367091 hasAuthorship W2325367091A5077384746 @default.
• W2325367091 hasAuthorship W2325367091A5079166921 @default.
• W2325367091 hasAuthorship W2325367091A5079218922 @default.
• W2325367091 hasAuthorship W2325367091A5082005832 @default.
• W2325367091 hasAuthorship W2325367091A5085612104 @default.
• W2325367091 hasAuthorship W2325367091A5087171601 @default.
• W2325367091 hasBestOaLocation W23253670911 @default.
• W2325367091 hasConcept C120665830 @default.
• W2325367091 hasConcept C121332964 @default.
• W2325367091 hasConcept C126322002 @default.
• W2325367091 hasConcept C141071460 @default.
• W2325367091 hasConcept C2776694085 @default.
• W2325367091 hasConcept C2777063308 @default.
• W2325367091 hasConcept C2778041864 @default.
• W2325367091 hasConcept C2778461978 @default.
• W2325367091 hasConcept C2778729363 @default.
• W2325367091 hasConcept C61511704 @default.
• W2325367091 hasConcept C71924100 @default.
• W2325367091 hasConcept C90924648 @default.
• W2325367091 hasConceptScore W2325367091C120665830 @default.
• W2325367091 hasConceptScore W2325367091C121332964 @default.
• W2325367091 hasConceptScore W2325367091C126322002 @default.

• next